Last year, smaller companies led in new drug approvals, according to a recent OutsourcingPharma.com article featuring Ken Getz, director of sponsored research at Tufts University. Notably, nearly half of these new drugs were for the treatment of rare diseases, demonstrating a shift within the industry away from a focus on scaling infrastructure.*
CEO and Founding Principal of BBK Worldwide, Joan F. Bachenheimer, responds to the article, explaining that “the precision aspects of clinical trial discovery have remapped the patient experience. The more targeted the investigational therapy, the more individualized the orientation becomes toward patient recruitment and engagement. It’s logical that the search for patients with specific biomarkers begets an orientation centered on individual needs versus a mass orientation."
Rare Disease Research,